Fisher Asset Management LLC cut its stake in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) by 2.1% in the fourth quarter, Holdings Channel reports. The firm owned 2,825,644 shares of the company’s stock after selling 60,698 shares during the quarter. Fisher Asset Management LLC owned 0.25% of iShares U.S. Pharmaceuticals ETF worth $239,699,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. Stratos Wealth Advisors LLC acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF during the fourth quarter worth $555,000. Accurate Wealth Management LLC acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF during the fourth quarter worth $6,372,000. D.A. Davidson & CO. acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF during the fourth quarter worth $1,709,000. Childress Capital Advisors LLC acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF during the fourth quarter worth $1,018,000. Finally, Anfield Capital Management LLC acquired a new stake in shares of iShares U.S. Pharmaceuticals ETF during the fourth quarter worth $10,007,000.
iShares U.S. Pharmaceuticals ETF Stock Performance
IHE stock opened at $91.51 on Tuesday. The business’s 50-day moving average price is $87.17 and its two-hundred day moving average price is $86.33. The firm has a market cap of $988.31 million, a PE ratio of 17.75 and a beta of 0.49. iShares U.S. Pharmaceuticals ETF has a 1-year low of $63.03 and a 1-year high of $92.29.
iShares U.S. Pharmaceuticals ETF Company Profile
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
See Also
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns
- Microsoft Stock Discount May Be Ending as AI Catalysts Build
- Apparel Earnings Winners and Losers: Ralph Lauren Takes Off
- Why Walmart, Target and TJX Got Such Different Reactions After Earnings
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
